Xalud Therapeutics, Inc.   Report issue

For profit Phase 3
Founded: San Francisco CA United States (2009)

Organization Overview

First Clinical Trial
2018
NCT03282149
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Xalud Therapeutics | Xalud Therapeutics, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

xt-150 (7 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neuralgia (Phase 1)

Osteoarthritis (Phase 3)

Osteoarthritis, Knee (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 1